Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vera Therapeutics

< Previous 1 2 Next >
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Scheduled to Present at November Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Scheduled to Present at September Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Present at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.